Astria Therapeutics to Present at Upcoming Oppenheimer 35th Annual Healthcare Life Sciences Conference
Astria Therapeutics (NASDAQ:ATXS), a biopharmaceutical company specializing in allergic and immunologic disease therapies, has announced its upcoming participation in the Oppenheimer 35th Annual Healthcare Life Sciences Conference. The company's CEO, Dr. Jill C. Milne, will engage in a fireside chat on Tuesday, February 11th at 10:40am ET.
The presentation will be accessible via webcast, with a replay available on the company's investor website for 30 days following the event. This virtual conference appearance represents an opportunity for Astria to showcase its developments in life-changing therapies to the investment community.
Astria Therapeutics (NASDAQ:ATXS), un'azienda biofarmaceutica specializzata nelle terapie per le malattie allergiche e immunologiche, ha annunciato la sua prossima partecipazione alla 35ª Conferenza Annuale Oppenheimer sulle Scienze della Salute. L'amministratore delegato dell'azienda, Dr. Jill C. Milne, parteciperà a un incontro informale martedì 11 febbraio alle 10:40 ET.
La presentazione sarà accessibile tramite webcast, con una riproduzione disponibile sul sito web per gli investitori dell'azienda per 30 giorni dopo l'evento. Questa apparizione alla conferenza virtuale rappresenta un'opportunità per Astria di mettere in mostra i propri sviluppi in terapie che cambiano la vita alla comunità degli investitori.
Astria Therapeutics (NASDAQ:ATXS), una empresa biofarmacéutica especializada en terapias para enfermedades alérgicas e inmunológicas, ha anunciado su próxima participación en la 35ª Conferencia Anual Oppenheimer sobre Ciencias de la Salud. La directora ejecutiva de la empresa, la Dra. Jill C. Milne, participará en una charla informal el martes 11 de febrero a las 10:40 ET.
La presentación será accesible a través de un webcast, con una repetición disponible en el sitio web para inversionistas de la empresa durante 30 días después del evento. Esta aparición en la conferencia virtual representa una oportunidad para que Astria muestre sus desarrollos en terapias que cambian la vida a la comunidad de inversores.
Astria Therapeutics (NASDAQ:ATXS), 알레르기 및 면역 질환 치료를 전문으로 하는 생물 제약 회사가 오펜하이머 제35회 연례 의료 생명 과학 회의에 참여할 것이라고 발표했습니다. 회사의 CEO인 Jill C. Milne 박사는 2월 11일 화요일 오전 10:40 ET에 편안한 대화를 진행할 예정입니다.
프레젠테이션은 웹캐스트를 통해 접근 가능하며, 이벤트 후 30일 동안 회사의 투자자 웹사이트에서 다시 볼 수 있습니다. 이번 가상 회의 출연은 Astria가 투자 커뮤니티에 삶을 변화시키는 치료법의 발전을 보여줄 수 있는 기회를 나타냅니다.
Astria Therapeutics (NASDAQ:ATXS), une entreprise biopharmaceutique spécialisée dans les thérapies pour les maladies allergiques et immunologiques, a annoncé sa prochaine participation à la 35e Conférence Annuelle Oppenheimer sur les Sciences de la Santé. La directrice générale de l'entreprise, Dr. Jill C. Milne, participera à une discussion informelle le mardi 11 février à 10h40 ET.
La présentation sera accessible par webcast, avec une rediffusion disponible sur le site Web des investisseurs de l'entreprise pendant 30 jours après l'événement. Cette apparition à la conférence virtuelle représente une opportunité pour Astria de présenter ses développements en thérapies transformant la vie à la communauté d'investisseurs.
Astria Therapeutics (NASDAQ:ATXS), ein biopharmazeutisches Unternehmen, das auf Therapien für allergische und immunologische Erkrankungen spezialisiert ist, hat seine bevorstehende Teilnahme an der 35. Jahreskonferenz Oppenheimer für Gesundheitswissenschaften bekannt gegeben. Der CEO des Unternehmens, Dr. Jill C. Milne, wird am Dienstag, den 11. Februar, um 10:40 Uhr ET an einem informellen Gespräch teilnehmen.
Die Präsentation wird über einen Webcast zugänglich sein, mit einer Wiederholung, die für 30 Tage nach der Veranstaltung auf der Investorenseite des Unternehmens verfügbar ist. Dieses virtuelle Konferenz-Engagement bietet Astria die Möglichkeit, ihre Entwicklungen in lebensverändernden Therapien der Investoren-Community vorzustellen.
- None.
- None.
A webcast of the presentation can be accessed at the following link: https://wsw.com/webcast/oppenheimer39/atxs/2823424. An archived replay of the presentation will be available in the investors section of www.astriatx.com for 30 days following the event.
About Astria Therapeutics:
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by allergic and immunologic diseases. Our lead program, navenibart (STAR-0215), is a monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema. Our second program, STAR-0310, is a monoclonal antibody OX40 antagonist in clinical development for the treatment of atopic dermatitis. Learn more about our company on our website, www.astriatx.com, or follow us on Instagram @AstriaTx and on Facebook and LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250204912062/en/
Investor Relations and Media:
Elizabeth Higgins
investors@astriatx.com
Source: Astria Therapeutics, Inc.
FAQ
When is Astria Therapeutics (ATXS) presenting at the Oppenheimer Healthcare Conference?
How can investors watch Astria Therapeutics' (ATXS) Oppenheimer Conference presentation?
What type of presentation will ATXS deliver at the Oppenheimer Healthcare Conference?
How long will the ATXS Oppenheimer Conference presentation replay be available?
